Eterna Therapeutics

Historical price data

Eterna Therapeutics is advancing a pipeline of allogeneic, synthetic cell therapies targeting high-need areas in oncology and autoimmune diseases. The company's core technology engineers iPSC-derived mesenchymal stem cells (iMSCs) to function as targeted delivery vehicles for cytokines like IL-7/IL-15 and IL-10 directly to disease sites. With lead candidate ERNA-101 advancing towards the clinic for platinum-resistant ovarian cancer, the company's strategy focuses on demonstrating proof-of-concept in a challenging indication with significant unmet need, while leveraging a scalable platform for broader applications. Eterna operates as a public company, trading on the NASDAQ under the ticker ERNA.

Proprietary platform engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) designed to home to disease sites and deliver targeted immunomodulatory cytokine payloads, enabling scalable, off-the-shelf cell therapies.

Ernexa competes with well-funded iPSC cell therapy companies (e.g., Fate Therapeutics, Century Therapeutics) and a broad array of oncology/autoimmune biologics. Its niche is engineering iMSCs as targeted cytokine delivery vehicles, a differentiated strategy that must now prove its advantages in the clinic against established and emerging modalities.